Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer. (19th November 2012)

• Record Type: Journal Article
• Authors: Takakura, Michiko; Yokomizo, Akira; Tanaka, Yoshinori; Kobayashi, Michimoto; Jung, Giman; Banno, Miho; Sakuma, Tomohiro; Imada, Kenjiro; Oda, Yoshinao; Kamita, Masahiro; Honda, Kazufumi; Yamada, Tesshi; Naito, Seiji; Ono, Masaya
• Other Names: Bilsland A. E. Academic Editor.; Comin-Anduix B. Academic Editor.; Ferrandina G. Academic Editor.; Holdenrieder S. Academic Editor.
• Is Part Of: ISRN oncology. Volume 2012(2012)
• Publication Date: 2012-11-19
• Subjects: Oncology -- Periodicals; Neoplasms; Oncology; Periodicals; 616.994
• DOI: 10.5402/2012/768190
• Languages: English
• ISSNs: 2090-5661

Abstract

Abstract : Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40, 678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (P = 0.022, Mann-Whitney U test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.